Baxter (NYSE:BAX) said today that its Evo IQ infusion system won CE Mark clearance and regulatory approval in Australia.
The company plans to start the launch process for its infusion system in the U.K., Ireland, New Zealand and Australia in the third quarter of this year.
Baxter’s Evo IQ infusion system includes an advanced drug library, dose-error reduction software and One Set technology designed to allow clinicians to switch between gravity and pump applications without changing sets.
“With the Evo IQ Infusion System, Baxter is extending its leading-edge infusion systems technology to help increase drug library compliance and protect patient infusions in the UK, Ireland, Australia, and New Zealand,” David Ferguson, GM of Baxter’s medication delivery unit, said in prepared remarks. “The Evo IQ Infusion System provides healthcare facilities with access to Baxter’s proven infusion safety technology in an adaptable system that can grow with their needs.”
At the time of launch, the Evo IQ system will include a large volumetric infusion pump, according to Baxter, with an additional pump and set offerings in the company’s pipeline.
